Globus Medical Earnings Call Shows Profitable Growth

Globus Medical ((GMED)) has held its Q4 earnings call. Read on for the main highlights of the call.

Globus Medical’s latest earnings call struck an upbeat tone as management highlighted record quarterly and annual results, expanding margins and faster‑than‑planned synergy capture from recent deals. While they acknowledged integration risks, uneven early‑year execution and a thinner cash cushion after acquisitions and buybacks, the overall message was one of confidence in sustained growth and profitability.

Record Top- and Bottom-Line Performance

Globus posted Q4 2025 revenue of $826.4 million, up 25.7% year over year, with constant‑currency growth of 24.7%. Non‑GAAP EPS surged 52.1% to $1.28 in the quarter, contributing to full‑year revenue of $2.939 billion, up 16.7%, and non‑GAAP EPS of $3.98, up a strong 30.8% versus 2024.

Core Spine and Base Business Momentum

The base business delivered Q4 revenue of $726.7 million, growing 10.6% year over year and driving 8.8% organic growth in the second half of 2025. U.S. Spine remained a standout with roughly 10% growth in Q4 and 48 consecutive weeks of gains, underscoring durable above‑market share capture in the company’s core franchise.

Enabling Technologies Regain Traction

Enabling Technologies delivered Q4 sales of $55.6 million, up 18.5% year over year, after earlier pipeline elongation created uneven results during the year. Management noted record unit and dollar sales across the capital portfolio and ExcelsiusGPS robotics, with several delayed deals finally closing late in the year.

Trauma and New Products Drive Upside

The trauma business accelerated with roughly 27% growth in Q4, benefiting from both legacy product strength and strong adoption of new systems. The ANTHEM elbow plating launch was singled out as a particular success, with surgeon demand and utilization running ahead of internal expectations.

Margins Expand as Scale and Synergies Kick In

Profitability improved sharply, with adjusted gross margin rising to 69.2% in Q4 from 67.1% a year ago. Legacy Globus delivered an adjusted EBITDA margin of 35.7% in the quarter and the consolidated business reached 33.9%, bringing the full‑year adjusted EBITDA margin to 31.3%.

NuVasive Synergies and Cash Flow Outperformance

Synergy execution from the NuVasive deal is running ahead of plan, with $200 million in actions already taken versus a $170 million target. This drove sequential P&L improvements and helped lift free cash flow to $202.4 million in Q4 2025, a roughly 150% jump from the $81.8 million generated in the prior‑year quarter.

Nevro Turns EPS-Accretive Ahead of Schedule

Nevro contributed $293.6 million of revenue for the year and $99.7 million in Q4, with a stand‑alone adjusted EBITDA margin of 21.2% in the quarter. Importantly for investors, Nevro became EPS accretive within the first nine months post‑acquisition, beating the original timeline by about 15 months despite a history of losses.

GAAP Profitability and Balance Sheet De-Risking

GAAP gross margin improved to 65.7% in Q4 from 57.2% a year earlier, helped by lower inventory step‑up amortization and synergy benefits. The company also fully repaid $450 million of convertible debt inherited from the merger, lowering interest expense and simplifying the capital structure.

Capital Allocation and Buybacks Support Shareholders

Management balanced internal investment with shareholder returns, repurchasing about 4.3 million shares for $300.5 million during 2025, including $45 million in Q4. Even after this activity, Globus still has $390 million remaining on its $500 million authorization, while it continues to prioritize CapEx at 5%–6% of sales.

Operational Lumpiness and Early-Year Missteps

The year did not start smoothly as Q1 performance disappointed and Enabling Technologies bookings remained uneven through much of 2025. These timing issues created choppy quarter‑to‑quarter results, though management emphasized that strong Q4 momentum demonstrates the underlying demand remains intact.

International Markets Face Supply and Regional Strains

International spine growth was hampered early in the year by supply shortages and regional volatility, especially in Asia‑Pacific and parts of Latin America. Conditions improved by Q4, when international revenue rose 19% or 14.2% in constant currency, but management still views the ex‑U.S. environment as somewhat choppy.

Cash Balance Shrinks After Heavy Outlays

Globus ended 2025 with $629.1 million in cash, cash equivalents and marketable securities, down from $956.2 million a year earlier. The decline reflects $450 million of debt repayment, the $252.5 million Nevro acquisition and $300.5 million in share repurchases, leaving the company with less liquidity headroom than before.

Nevro Integration Still Carries Execution Risk

While Nevro is already boosting EPS, management cautioned that integration is not fully complete and growth may be non‑linear in the near term. Investors were reminded that Nevro entered the deal having posted a $113 million net loss on $409 million of revenue in 2024, making ongoing execution critical to the value‑creation story.

High SG&A and One-Off Charges Pressure Near-Term Margins

Selling and administrative spending remained elevated, with Q4 SG&A at $318.5 million, or 38.5% of sales, including $13.4 million of estimated litigation charges. Nevro alone accounted for $49.8 million of SG&A, equivalent to nearly half of its Q4 sales, as integration and sales force investments temporarily weigh on efficiency.

Lease-Driven Enabling Tech Strategy Adds Volatility

Globus is leaning more on operating leases and flexible structures to place its robotics and navigation platforms, broadening access for hospitals. However, management acknowledged this approach can defer or smooth revenue recognition versus outright sales, potentially making near‑term Enabling Technologies revenue comparisons lumpy.

R&D Mix Shifts After Synergies, with Re-Acceleration Ahead

R&D spending fell to 5.0% of sales in 2025 and to just 4.4% of sales within legacy Globus in Q4 as cost synergies were realized. Management emphasized plans to lift R&D back to 5%–6% of sales in 2026 to sustain innovation, accepting some near‑term margin pressure in exchange for a healthier long‑term product pipeline.

Competitive Landscape Remains Dynamic

Executives noted that competition in robotics, navigation and spine implants continues to evolve, with new entrants and portfolio reshuffling across the industry. Globus aims to offset these pressures through ongoing product launches, targeted sales force expansion and more flexible pricing and deal structures.

Guidance Signals Confidence in Sustained Expansion

For 2026, Globus reaffirmed revenue guidance of $3.18 billion to $3.22 billion, implying 8.2%–9.6% growth, and raised non‑GAAP EPS guidance to $4.40–$4.50. The outlook calls for at least 100 basis points of adjusted gross margin expansion to 69%–70%, increased R&D to 5%–6% of sales, SG&A at 38%–39% and CapEx at 5%–6%, while recognizing that leasing and Nevro may keep results somewhat lumpy.

Globus Medical’s call painted the picture of a company successfully digesting major deals while still growing faster than its markets and expanding margins. Investors will need to monitor integration progress, spending discipline and cash levels, but management’s raised EPS outlook and accelerating cash flow suggest the long‑term trajectory remains firmly upward.